Vyome CEO Venkat Nelabhotla Unveils the ‘Develop, Own, Make, Commercialize’ Roadmap for Global Life Sciences Leadership in Mumbai
At the prestigious 17th Annual Healthcare Leadership Summit & Power Brand Awards, held at the Hilton Mumbai International Airport, Mr. Venkat Nelabhotla, the visionary Co-Founder, President, and CEO of Vyome Holdings, Inc. and Vyome Therapeutics, Inc., delivered a masterclass in biopharmaceutical sovereignty. His compelling address, titled “India’s Next Biotech and Pharma Innovation Leap: Develop, Own, Make, and Commercialize for the World,” served as an urgent, eloquent blueprint for the evolution of the Indian life sciences ecosystem.
Addressing a distinguished gathering of global healthcare captains, clinical pioneers, and policymakers, Mr. Nelabhotla challenged the traditional paradigm of India as merely the “pharmacy of the world” via generic volume. Instead, he articulated a bold, paradigm-shifting thesis rooted in intellectual property creation and global commercialization ownership.
Drawing from his illustrious 35-year career of scaling multi-billion-dollar entities and pioneering cross-border biotechs, Mr. Nelabhotla’s presentation was structured around four foundational pillars designed to elevate India from a cost-efficient manufacturer to an undisputed global innovation powerhouse:
- DEVELOP: Moving Up the Value Chain
He emphasized that the future belongs to biology-driven innovation. Using Vyome’s breakthrough clinical successes—such as the targeted development of their lead asset VT-1953 for malignant fungating wounds—he illustrated how India’s formidable scientific talent must transition from reverse-engineering to pioneering first-in-class, de-risked therapeutic solutions for profoundly underserved global indications.
- OWN: The Sovereignty of Intellectual Property (IP)
Mr. Nelabhotla argued passionately that true enterprise value lies in the ownership of the molecule. He detailed how Vyome has pioneered the “US-India Innovation Corridor,” leveraging India’s hyper-capital-efficient R&D infrastructure to create and own global assets, which are subsequently validated through rigorous US FDA regulatory pathways.
- MAKE: Institutionalizing Manufacturing Excellence
Building upon India’s world-class, compliant manufacturing base, he advocated for the rapid adoption of advanced bioprocessing, complex biologics, and novel drug delivery systems (NDDS) to ensure that Indian-made therapeutics meet the stringent, uncompromised quality standards of global markets.
- COMMERCIALLY TRIUMPH: Capturing the Global Value Share
The apex of his address focused on strategic corporate development. He underscored the critical importance of orchestrating sophisticated, backend-heavy global out-licensing structures and accessing elite global capital markets—reveling in Vyome’s historic milestone of transitioning to a debt-free, publicly-traded listing on the Nasdaq (Ticker: HIND).
The Definitive Takeaway:
Mr. Nelabhotla’s presentation concluded with a resounding clarion call for collaborative disruption. He reminded the audience that for India to orchestrate its next quantum leap, the industry must shed its risk-averse posture, embrace bold capital-efficient cross-border models, and aggressively pursue the commercialization of homegrown breakthrough science on the global stage. It was an inspiring, definitive roadmap that set the intellectual tone for the 2026 Summit.
